Vantis Vascular, Inc., a medical technology company focused on vascular interventions, announced FDA 510(k) clearance for its CrossFAST Integrated Microcatheter Guide Extension System. This system is designed to aid physicians in performing faster, easier, and safer procedures for complex coronary and peripheral interventions.
The CrossFAST system aims to improve navigation in complex, calcified, and tortuous anatomies. According to Tim Fischell, MD, Chief Medical Officer at Vantis, there is a significant need to improve existing guide extension catheters due to anatomical challenges and the increasing prevalence of complex high-risk patients. The CrossFAST System is designed for smooth and effortless deliverability, potentially revolutionizing access to target locations.
Technology and Design
Guide extension catheters are crucial in vascular interventions, providing support and facilitating device delivery in challenging anatomies. Traditional catheters often lack sufficient pushability and can risk vessel trauma during delivery. The CrossFAST Guide Extension System addresses these limitations with its patented DuoPro Interlocking Technology, a mechanism that couples the outer and inner extension catheters. This design enhances safety and deliverability, improving interventional procedures from start to finish.
Company Statement
Jason Turner, Chief Executive Officer at Vantis, stated that the FDA clearance marks a significant milestone in the company's mission to transform how physicians navigate complex and calcific anatomy. He added that the CrossFAST System reflects their commitment to addressing the real challenges physicians face in complex interventions, ultimately enabling better patient outcomes.
Market Availability
The CrossFAST Guide Extension System will be commercially available in the United States in Q4 2024 as part of a limited market release, with a full market release planned for 2025.
